AstraZeneca PLC Could Up Stake in Bristol-Myers Squibb Company Diabetes JV

Published: Nov 08, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca may seek to increase its stake in a diabetes joint venture with Bristol-Myers Squibb, following a decision by the U.S. firm to exit diabetes drug research, according to Citi. Bristol said on Thursday it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer. That refocusing suggests Bristol could seek to sell its share in the non-U.S. part of the diabetes joint venture to its partner AstraZeneca, Citi analyst Andrew Baum said in a note on Friday.

Help employers find you! Check out all the jobs and post your resume.

Back to news